Innovation at Prosit Sole
Video Display
-
Our Vision and Mission at Prosit Sole -- By CEO of Prosit Sole Dr. Hongyu Liu
-
Why Prosit Sole is one of the most potential orphan drugs biopharma? By Former VP of Novo-Nordisk
Former VP of Novo-Nordisk -
Opinion From Board Director Don D. -- Funder of Rotating Boulder Fund
Founder of Rotating Boulder Fund
Former CEO of KPC Pharmaceuticals Group -
Experts Opinion-- BY Board Director Christian E. , CEO of Lundbeck Found
CEO of Lundbeck Found Talked About Prosit Sole
Press Release
-
Phase 1 Sigle Ascending Dose Clinical Trail in 42 Health Volunteers
2022-07-01A total number of 42 subjects were randomized into the Phase 1a single ascending dose (SAD) study. The data exhibit good safety profile of PSP001. No serious treatment-emergent adverse events in the 42 subjects were noted. -
Prosit Sole had initiated the first-in-human (“FIH”) Phase I clinical trial of PSP001 in US
2021-05-28Baltimore, USA, May26,2021&/--PrositSole Biotechnology, a clinical-stage biotech company developing novel protein therapeutics, today announces that it has initiated the FIH clinical trial of PSP001 in the US.
About Prosit Sole
Unmet Medical Needs, Our Social Responsibility
At Prosit Sole, we focus on developing innovative protein therapeutics that address the unmet medical needs for life-threatening rare diseases. Prosit Sole established an advanced Prositsole Protein Optimize Platform (P-POP), a Biologics discovery technology, patented in the US and China, that enables us to discover first-in-class or best-in-class biologics, with excellent efficacy and favorable safety profile. Currently, Prosit Sole has 4 Biologics in various stages of development, the lead product candidates are PEGINF-lchimeric (currently being pursued for IND in the US) and a FGF-18 chimeric (currently in pre-clinical development).
